A benchtop bioreactor system developed at Hannover Medical School can produce up to 40 million human immune cells per week from stem cells, according to a protocol published in Nature Protocols in early 2025. The system runs four small vessels in parallel, each generating roughly 20 to 30 million macrophages per harvest, and sustains that output across at least 10 weeks of continuous operation.
Macrophages are the immune system’s first responders. They engulf bacteria, clear dead cells, and coordinate inflammatory signals. Researchers need large, consistent batches of them to screen drug candidates, study infections, and develop cell-based therapies for diseases ranging from antibiotic-resistant pneumonia to solid tumors. Until now, getting enough has meant either drawing blood from human donors, which yields variable cells in limited quantities, or scaling up industrial bioreactors that most academic labs cannot afford.
The Hannover system, led by Prof. Nico Lachmann, threads a middle path: vessels in the 10 to 50 mL range that fit on a standard lab bench yet deliver cell counts in the tens of millions weekly.
How the system works
The process begins with induced pluripotent stem cells (iPSCs), adult cells reprogrammed to behave like embryonic stem cells. Seeded into stirred suspension culture, the iPSCs form aggregates that are then guided through a differentiation sequence using specific growth factors. Over several weeks, these aggregates begin shedding mature macrophages into the surrounding media, much like fruit dropping from a tree on a recurring cycle.
Each of the four vessels is harvested independently, and the protocol calls for at least five consecutive collections per vessel. According to the Nature Protocols paper, individual harvests yield roughly 20 to 30 million macrophages. Running all four vessels on staggered schedules produces the headline figure of up to 40 million cells per week.
This approach builds on a clear technical lineage from the same research group. A 2018 study in Nature Communications first demonstrated that stirred-tank bioreactors could sustain weekly macrophage harvests of 10 to 30 million cells for more than five weeks, with continuous process monitoring. A follow-up protocol published in Nature Protocols in 2022 laid out step-by-step operating parameters so other labs could replicate the method. The new publication extends that foundation by multiplying output through parallel vessels rather than by enlarging a single reactor.
Why iPSC-derived macrophages matter
Macrophages isolated from blood donors vary from person to person and batch to batch. That inconsistency is a problem for pharmaceutical companies running drug screens, where reproducibility is everything. iPSC-derived macrophages, by contrast, come from a single, well-characterized cell line. Every batch is genetically identical, and the cells can be gene-edited before differentiation to model specific diseases or test targeted therapies.
A separate peer-reviewed study confirmed that macrophages produced through these bioreactor methods retain the identity markers and functional behavior needed for drug screening. They phagocytose bacteria, respond to inflammatory signals, and polarize into pro- or anti-inflammatory states, all hallmarks of naturally occurring macrophages. Without that functional validation, raw cell counts would be meaningless.
The 2018 Nature Communications study also showed that bioreactor-grown macrophages could function in animal models of bacterial airway infection, a result that points toward potential therapeutic applications in diseases like ventilator-associated pneumonia or cystic fibrosis lung infections.
What has not been proven yet
The 40 million weekly figure deserves careful reading. It represents the upper bound of what the system can deliver when all four vessels hit the high end of their yield range simultaneously. The per-vessel output reported in Nature Protocols spans 20 to 30 million cells per harvest, and the earlier Nature Communications work reported an even wider band of 10 to 30 million. Real-world output will vary depending on iPSC line quality, media preparation, and operator experience.
The aggregate 40 million number also appears in an institutional summary from Hannover Medical School rather than in a specific data table within the protocol itself. It is consistent with the published per-vessel figures but should be understood as a projected ceiling, not a guaranteed weekly yield.
No independent laboratory has yet published a replication of the multi-vessel protocol. A troubleshooting guide in STAR Protocols addresses common failure points in iPSC-to-macrophage differentiation, including cytokine handling and media issues, but it was written for general workflows and does not cover the specific challenges of coordinating four bioreactors at once.
Cost data is also absent. The Hannover team has not disclosed what it takes to run four vessels continuously for 10 weeks, including media, cytokines, and labor. For academic labs considering adoption, that information will be critical.
Most importantly, no human clinical trial has used bioreactor-grown macrophages from any group. The animal data is encouraging, but the gap between a mouse lung infection model and a patient receiving a macrophage infusion remains vast. No timeline for clinical trials appears in any of the published literature as of May 2025.
What comes next for lab-grown immune cells
The practical significance of this work is not the 40 million number alone. It is that a reproducible, peer-reviewed protocol now exists for generating tens of millions of functional human macrophages per week using equipment that fits on a laboratory bench. The step-by-step instructions and defined operating parameters lower the barrier for other research groups to adopt the technique, test it against their own iPSC lines, and push the yields further.
Whether the method can scale to hundreds of millions of cells per week, the range likely needed for therapeutic doses, will depend on engineering advances not yet published. But for drug screening, disease modeling, and early-stage immunotherapy research, the current output may already be enough to shift how labs source their macrophages. The days of relying solely on blood donors for these cells may be numbered.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
